These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2857291)

  • 21. Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide.
    Vellodi A; Jurges E; el-Tumi M; Abdul-Ahad A; Hobbs JR
    Bone Marrow Transplant; 1991; 7 Suppl 2():70. PubMed ID: 1878726
    [No Abstract]   [Full Text] [Related]  

  • 22. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
    Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation.
    Caselli D; Rosati A; Faraci M; Podda M; Ripaldi M; Longoni D; Cesaro S; Lo Nigro L; Paolicchi O; Maximova N; Menconi MC; Ziino O; Cicalese MP; Santarone S; Nesi F; Aricò M; Locatelli F; Prete A;
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):282-5. PubMed ID: 24201160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of destruction and regeneration of the haemopoietic system after administration of busulphan and cyclophosphamide followed by bone marrow transplantation. Peripheral blood parameters.
    Szczylik C; Ratajczak MZ; Urbanowska E; Jedrzejczak WW
    Acta Med Pol; 1989; 30(3-4):93-109. PubMed ID: 2519630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
    Shaw PJ; Nath C; Berry A; Earl JW
    Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
    Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
    Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Busulphan/cyclophosphamide for CML.
    Mccann SR; Murray M
    Bone Marrow Transplant; 1988 Jul; 3(4):368. PubMed ID: 3167262
    [No Abstract]   [Full Text] [Related]  

  • 28. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.
    Bakker B; Oostdijk W; Bresters D; Walenkamp MJ; Vossen JM; Wit JM
    Bone Marrow Transplant; 2004 May; 33(10):1049-56. PubMed ID: 15048143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
    Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
    Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy.
    Thomas AE; Patterson J; Prentice HG; Brenner MK; Ganczakowski M; Hancock JF; Pattinson JK; Blacklock HA; Hopewell JP
    Bone Marrow Transplant; 1987 Apr; 1(4):347-55. PubMed ID: 3139113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute leukaemia after busulphan.
    Stott H; Fox W; Girling DJ; Stephens RJ; Galton DA
    Br Med J; 1977 Dec; 2(6101):1513-7. PubMed ID: 589308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.
    Hempel G; Oechtering D; Lanvers-Kaminsky C; Klingebiel T; Vormoor J; Gruhn B; Boos J
    J Clin Oncol; 2007 May; 25(13):1772-8. PubMed ID: 17470868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
    Rubie H; Attal M; Demur C; Brousset P; Duchayne E; Rigal-Huguet F; Dastugue N; Robert A
    Bone Marrow Transplant; 1994 Jun; 13(6):759-62. PubMed ID: 7920311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal prevention of seizures induced by high-dose busulfan.
    Eberly AL; Anderson GD; Bubalo JS; McCune JS
    Pharmacotherapy; 2008 Dec; 28(12):1502-10. PubMed ID: 19025431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early post-BMT liver function in children with acute leukemia conditioned for allo-BMT with Busulfan-containing and with FTBI-containing preparative regimens.
    Wachowiak J; Boruczkowski D; Malicki J; Chobot-Musiałkiewicz U
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S96-9. PubMed ID: 9916649
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of myleran therapy in multitransfused thalassemic children.
    Lal A; Pati HP; Arya LS; Choudhry VP
    Indian Pediatr; 1995 Feb; 32(2):238-41. PubMed ID: 8635790
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of liposomal busulphan in man.
    Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
    Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
    Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
    Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.
    Hobbs JR; Hugh-Jones K; Shaw PJ; Downie CJ; Williamson S
    Bone Marrow Transplant; 1986 Dec; 1(2):201-8. PubMed ID: 2971409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.